News Releases

FDA Grants Special Designation to TAXIS Pharmaceuticals Experimental Antibiotic: Compound Named a Qualified Infectious Disease Product (QIDP) for Acute Bacterial Skin and Skin Structure Infections

September 7, 2016Read More Download

TAXIS PHARMACEUTICALS DEMONSTRATES SYNERGISTIC EFFICACY AGAINST MRSA AND LOW RESISTANCE FREQUENCY WITH TXA709/CEFDINIR COMBINATION: Poster Presentation at ICAAC 2015 Highlights Potential of TXA709, Both Alone and in Combination with Cefdinir, as Oral Antibiotic for Drug-Resistant S. aureus Infections

September 18, 2015Read More Download

TAXIS PHARMACEUTICALS DEMONSTRATES CLINICAL POTENTIAL OF TXA709 IN COMBATING ANTIBIOTIC RESISTANCE: Poster Presentation at ECCMID 2015 Highlights Unique Mechanism of Action and Potent Bactericidal Activity against MRSA Strains

April 27, 2015Read More Download

TAXIS acquires novel antimicrobial drug candidates from Biota

August 11, 2014Read More Download

TAXIS Pharmaceuticals Moves to High-Tech Business Incubator Developer of Novel Antibiotics Accepted at the Tech Centre of New Jersey

September 22, 2010Read More Download

Rutgers-UMDNJ License Agreement: September 4, 2009

September 4, 2009Read More Download